KRAS G12D Inhibitor–Irinotecan Combinations for Intrinsic Resistance
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current KRas G12D inhibitors and irinotecan treatments exhibit varying potency and efficacy due to intrinsic resistance in certain cell lines, necessitating alternative approaches to maximize their therapeutic index and clinical benefit.
Innovation Solution
Combining irinotecan or its analogs with a KRas G12D inhibitor, such as MRTX1133, to enhance the potency and efficacy of cancer treatment, particularly for KRas G12D-associated cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If KRas G12D inhibitors are used as single agent therapy, then they exhibit intrinsic resistance in certain cell lines, but combination with irinotecan increases potency and efficacy
Solution Approach 1:
The patent combines KRas G12D inhibitors with irinotecan or its analogs into a unified treatment regimen. This merging of two different therapeutic agents addresses the intrinsic resistance problem by attacking the cancer cells through multiple mechanisms simultaneously - the KRas inhibitor blocks the mutated protein pathway while irinotecan exerts its cytotoxic effects through topoisomerase inhibition, thereby overcoming resistance that would limit single-agent therapy.
2Manufacturing precision
If KRas G12D inhibitors are developed to target specific mutations, then they show potency against KRas G12D-associated cancers, but varying efficacy is observed across different cell lines
Solution Approach 1:
The patent modifies the treatment parameters by introducing combination therapy rather than relying solely on the KRas inhibitor monotherapy. This parameter change - adding irinotecan to the regimen - compensates for the varying efficacy across different cell lines by providing an additional mechanism of action that works synergistically with the KRas inhibition, thereby achieving more consistent therapeutic outcomes across diverse cancer cell types.
Data Source
AI summary
The present invention relates to combination therapies for treating KRas G12D cancers. In particular, the present invention relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a combination of irinotecan (or an analog thereof) and a KRas G12D inhibitor, pharmaceutical compositions comprising a such compositions, kits comprising such compositions and methods of use thereof.